혈액 스크리닝 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of blood screening Market

The global blood screening market size was valued at USD 3.56 billion in 2025 and is projected to grow from USD 3.90 billion in 2026 to USD 8.20 billion by 2034, exhibiting a CAGR of 9.73% during the forecast period. North America dominated the global market with a 41.86% share in 2025. The market is gaining momentum due to increasing blood donations, growing awareness of transfusion safety, rising infectious diseases, and government initiatives aimed at improving the safety of donated blood.

Blood screening tests are designed to identify markers of transfusion-transmissible infections (TTIs) and help ensure the safety of donated blood units. The increasing adoption of automated molecular platforms is further improving screening accuracy and reducing manual errors in blood banks, hospitals, and laboratories.

Market Definition and Scope

Blood screening includes diagnostic testing of donated blood to identify infectious disease markers and other risks that could affect transfusion safety. Technologies used in the market include molecular tests and serology tests, while products are broadly divided into reagents & kits and instruments.

The market is analyzed across product type, technology, end user, and geographical regions. Increasing blood transfusion procedures and improvements in laboratory infrastructure are expected to support the market through 2034.

Blood Screening Market Trends

Introduction of Automated Molecular Platforms

The transition from manual to automated blood screening platforms is one of the major market trends. Automated systems can improve testing efficiency, reduce human error, and support rapid detection of infectious diseases.

Molecular technologies, particularly nucleic acid testing (NAT), provide high sensitivity for detecting viral nucleic acids. The introduction of advanced automated platforms by leading diagnostic companies is encouraging their adoption across blood donation centers and clinical laboratories.

Blood Screening Market Growth Factors

Increasing Number of Blood Donations

The growing number of blood donations and donors is creating consistent demand for screening procedures. Government organizations, healthcare institutions, and nonprofit organizations are increasing awareness regarding voluntary blood donation and transfusion safety.

Growing demand for blood in accident treatment, cancer care, surgeries, and other medical procedures is also increasing the importance of screening. As blood utilization increases, healthcare providers require reliable testing procedures to minimize the risk of transfusion-transmitted infections.

Rising Prevalence of Infectious Diseases

The continued prevalence of infections such as HIV, hepatitis B, hepatitis C, syphilis, and other transfusion-transmissible diseases is encouraging healthcare systems to strengthen blood screening practices. Greater awareness of blood safety and improvements in diagnostic technologies are further supporting market adoption.

Restraining Factors

High Instrument Costs and Inadequate Infrastructure

High costs associated with advanced blood screening instruments can restrict adoption, particularly in emerging economies. Several developing markets continue to face limitations in healthcare infrastructure, laboratory capacity, trained personnel, and investment in advanced screening technologies.

Stringent regulatory requirements and the need for sophisticated testing facilities can further increase the cost of blood screening programs and limit market penetration in underdeveloped healthcare systems.

Blood Screening Market Segmentation Analysis

By Product Type

The reagents & kits segment is expected to maintain its leading position, accounting for 83.5% of the market in 2025. These products are consumed in large volumes for repeated blood screening procedures and are generally more affordable than screening instruments.

The instruments segment is expected to grow at a comparatively slower pace because instruments are reusable and have longer operating lifecycles. However, automation and technological improvements are expected to support demand for advanced instruments.

By Technology

The market is divided into molecular tests and serology tests. Molecular testing is supported by the high sensitivity of NAT for detecting viral nucleic acids and enabling early identification of infections such as HIV, HBV, and HCV.

Serology testing remains important because techniques such as ELISA and chemiluminescence immunoassay provide cost-effective options, particularly in emerging markets.

By End User

End users include independent clinical laboratories and hospital-based laboratories. Hospital-based laboratories are expected to gain importance through 2026 because of increasing blood transfusion procedures and the implementation of patient blood management programs.

Regional Blood Screening Market Analysis

North America

North America remains the leading regional market, supported by a large donor population, high awareness of blood safety, advanced healthcare infrastructure, and widespread adoption of screening technologies. The region accounted for 41.86% of the global market in 2025.

Europe

Europe is expected to witness steady growth, supported by advanced healthcare systems and increasing adoption of modern blood screening technologies. The region is projected to register a 7.3% CAGR during the forecast period.

Asia Pacific

Asia Pacific is expected to record significant growth as healthcare investments increase and diagnostic infrastructure improves. China and India represent important opportunities due to their large populations, increasing patient affordability, and rising healthcare requirements.

U.S. and Japan

The U.S. market is expected to grow steadily because of advanced laboratory infrastructure and high demand for safe blood products. The Japan blood screening market is expected to reach USD 208.2 million in 2025, supported by its established healthcare and diagnostic systems.

Competitive Landscape

The competitive landscape includes companies focusing on automated platforms, molecular diagnostics, product launches, acquisitions, and technological innovation. Major companies include Bio-Rad Laboratories, Grifols, F. Hoffmann-La Roche, Ortho Clinical Diagnostics, BD, DiaSorin, Thermo Fisher Scientific, Abbott, and QUOTIENT.

Key Industry Developments

Leading companies have continued introducing advanced blood screening and molecular diagnostic technologies. Grifols expanded its NAT capabilities through the acquisition of a manufacturing facility, while other diagnostic companies have introduced automated platforms and blood-based testing technologies for infectious diseases and broader screening applications.

Future Outlook

The blood screening market outlook remains positive as healthcare systems increasingly prioritize transfusion safety and automated diagnostics. Growing blood donation volumes, rising infectious disease concerns, technological advances in molecular testing, and expansion of hospital laboratory infrastructure are expected to support market growth through 2034.

Report Coverage

The blood screening market report provides detailed Market Analysis covering market size, market value, product types, technologies, end users, regional performance, market trends, growth factors, restraints, competitive landscape, and key industry developments. It also examines the adoption of automated screening platforms, molecular testing technologies, laboratory infrastructure, and strategies adopted by leading companies.

Conclusion

The global blood screening market is projected to expand from USD 3.56 billion in 2025 to USD 3.90 billion in 2026 and USD 8.20 billion by 2034. Increasing blood donations, greater awareness of transfusion safety, infectious disease prevalence, and the adoption of automated molecular screening platforms will remain major growth drivers. Reagents & kits and molecular testing are expected to remain important market segments, while improvements in healthcare infrastructure and advanced diagnostic technologies will create further opportunities across emerging and developed markets.

Unit Value (USD billion)

Segmentation By Product Type

• Instruments
• Reagents & Kits

By Technology

• Molecular Tests
• Serology Tests

By End User

• Independent Clinical Laboratories
• Hospital-based Laboratories
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Technology Advances, Blood Screening Techniques
• 4.2. Key Developments: Mergers, Partnerships, New Product Launches, etc.
• 4.3. Number of Blood Donations: Key Countries, 2025
• 4.4. Regulatory Scenario, Key Regions
• 4.5. Overview: Government Initiatives Towards Blood Donations

5. Global Blood Screening Market Analysis, Insights and Forecast, 2025-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Product Type
  • 5.2.1. Instruments
  • 5.2.2. Reagents & Kits
• 5.3. Market Analysis, Insights and Forecast - By Technology
  • 5.3.1. Molecular Tests
  • 5.3.2. Serology Tests
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Independent Clinical Laboratories
  • 5.4.2. Hospital-based Laboratories
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Country
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Blood Screening Market Analysis, Insights and Forecast, 2025-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Product Type
  • 6.2.1. Instruments
  • 6.2.2. Reagents & Kits
• 6.3. Market Analysis, Insights and Forecast - By Technology
  • 6.3.1. Molecular Tests
  • 6.3.2. Serology Tests
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Independent Clinical Laboratories
  • 6.4.2. Hospital-based Laboratories
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Blood Screening Market Analysis, Insights and Forecast, 2025-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Product Type
  • 7.2.1. Instruments
  • 7.2.2. Reagents & Kits
• 7.3. Market Analysis, Insights and Forecast - By Technology
  • 7.3.1. Molecular Tests
  • 7.3.2. Serology Tests
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Independent Clinical Laboratories
  • 7.4.2. Hospital-based Laboratories
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Blood Screening Market Analysis, Insights and Forecast, 2025-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Product Type
  • 8.2.1. Instruments
  • 8.2.2. Reagents & Kits
• 8.3. Market Analysis, Insights and Forecast - By Technology
  • 8.3.1. Molecular Tests
  • 8.3.2. Serology Tests
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Independent Clinical Laboratories
  • 8.4.2. Hospital-based Laboratories
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Blood Screening Market Analysis, Insights and Forecast, 2025-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Product Type
  • 9.2.1. Instruments
  • 9.2.2. Reagents & Kits
• 9.3. Market Analysis, Insights and Forecast - By Technology
  • 9.3.1. Molecular Tests
  • 9.3.2. Serology Tests
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Independent Clinical Laboratories
  • 9.4.2. Hospital-based Laboratories
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Blood Screening Market Analysis, Insights and Forecast, 2025-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Product Type
  • 10.2.1. Instruments
  • 10.2.2. Reagents & Kits
• 10.3. Market Analysis, Insights and Forecast - By Technology
  • 10.3.1. Molecular Tests
  • 10.3.2. Serology Tests
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Independent Clinical Laboratories
  • 10.4.2. Hospital-based Laboratories
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles
  • 11.3.1. Bio-Rad Laboratories, Inc
    • 11.3.1.1. Overview,
    • 11.3.1.2. Products,
    • 11.3.1.3. SWO,
    • 11.3.1.4. Recent Developments,
    • 11.3.1.5. Strategies,
    • 11.3.1.6. Financials (based on availability)
  • 11.3.2. Grifols, S.A.
    • 11.3.2.1. Overview,
    • 11.3.2.2. Products,
    • 11.3.2.3. SWO,
    • 11.3.2.4. Recent Developments,
    • 11.3.2.5. Strategies,
    • 11.3.2.6. Financials (based on availability)
  • 11.3.3. F. Hoffmann-La Roche
    • 11.3.3.1. Overview,
    • 11.3.3.2. Products,
    • 11.3.3.3. SWO,
    • 11.3.3.4. Recent Developments,
    • 11.3.3.5. Strategies,
    • 11.3.3.6. Financials (based on availability)
  • 11.3.4. Ortho Clinical Diagnostics
    • 11.3.4.1. Overview,
    • 11.3.4.2. Products,
    • 11.3.4.3. SWO,
    • 11.3.4.4. Recent Developments,
    • 11.3.4.5. Strategies,
    • 11.3.4.6. Financials (based on availability)
  • 11.3.5. DiaSorin S.p.A.
    • 11.3.5.1. Overview,
    • 11.3.5.2. Products,
    • 11.3.5.3. SWO,
    • 11.3.5.4. Recent Developments,
    • 11.3.5.5. Strategies,
    • 11.3.5.6. Financials (based on availability)
  • 11.3.6. BD
    • 11.3.6.1. Overview,
    • 11.3.6.2. Products,
    • 11.3.6.3. SWO,
    • 11.3.6.4. Recent Developments,
    • 11.3.6.5. Strategies,
    • 11.3.6.6. Financials (based on availability)
  • 11.3.7. Thermo Fisher Scientific Inc.
    • 11.3.7.1. Overview,
    • 11.3.7.2. Products,
    • 11.3.7.3. SWO,
    • 11.3.7.4. Recent Developments,
    • 11.3.7.5. Strategies,
    • 11.3.7.6. Financials (based on availability)
  • 11.3.8. Abbott
    • 11.3.8.1. Overview,
    • 11.3.8.2. Products,
    • 11.3.8.3. SWO,
    • 11.3.8.4. Recent Developments,
    • 11.3.8.5. Strategies,
    • 11.3.8.6. Financials (based on availability)
  • 11.3.9. Quotient
    • 11.3.9.1. Overview,
    • 11.3.9.2. Products,
    • 11.3.9.3. SWO,
    • 11.3.9.4. Recent Developments,
    • 11.3.9.5. Strategies,
    • 11.3.9.6. Financials (based on availability)
  • 11.3.10. Other Players
    • 11.3.10.1. Overview,
    • 11.3.10.2. Products,
    • 11.3.10.3. SWO,
    • 11.3.10.4. Recent Developments,
    • 11.3.10.5. Strategies,
    • 11.3.10.6. Financials (based on availability)

12. Strategic Recommendations